Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 02, 2015 6:34 PM ET


Company Overview of Heptares Therapeutics Ltd.

Company Overview

Heptares Therapeutics Ltd., a clinical-stage company, creates novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a range of human diseases. It offers GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, NCE discovery, and antibody discovery. The company was founded in 2007 and is based in Welwyn Garden City, United Kingdom. As of February 22, 2015, Heptares Therapeutics Ltd. operates as a subsidiary of Sosei Group Corporation.


Broadwater Road

Welwyn Garden City,  AL7 3AX

United Kingdom

Founded in 2007


44 17 0735 8628


44 17 0735 8640

Key Executives for Heptares Therapeutics Ltd.

Founder, Chairman and Chief Executive Officer
Age: 57
Founder, Chief Scientific Officer and Director
Age: 51
President of USA Operations
Age: 48
Chief Medical Officer and Vice President of Development
Age: 62
Chief Business Officer
Compensation as of Fiscal Year 2015.

Heptares Therapeutics Ltd. Key Developments

Heptares Therapeutics Reports Positive Outcome of its Phase 1a Study with HTL9936

Sosei Group Corporation announced that Heptares Therapeutics has reported the positive outcome of its Phase 1a study with HTL9936, the first-ever fully selective muscarinic M1 receptor agonist to enter clinical development. The Phase 1a study assessed the safety, tolerability and pharmacokinetics of HTL9936 in relation to dose in 84 healthy volunteers, while also evaluating preliminary signs of efficacy (increase in brain activity). Key findings were: Early evidence of increased brain activity, as measured by electroencephalography (EEG), was seen after dosing and gave signals similar to those seen with other cognitive enhancing agents; HTL9936 was well tolerated at drug levels that result in the increased brain activity observed without side effects; HTL9936 demonstrates good penetration into the brain, as indicated by levels found in cerebrospinal fluid; M1 selectivity was demonstrated with, unlike earlier muscarinic agonists3, no adverse effects seen from stimulation of other muscarinic receptors. These preliminary data suggest that the selective M1 agonist product profile of HTL9936 predicted from preclinical studies translates to humans. Heptares is now putting in place a series of further clinical studies with the objective of demonstrating clinical proof of concept in patients, and moreover is advancing its diverse portfolio of follow-on selective muscarinic agonists that target M1, M4, and both M1/M4 to the clinic.

Sosei Group Corporation, Heptares Therapeutics Ltd. - M&A Call

Sosei Group Corporation, Heptares Therapeutics Ltd. - M&A Call

Heptares Therapeutics Ltd. Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 through Mar-04-2015

Heptares Therapeutics Ltd. Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 through Mar-04-2015. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Zurich, Switzerland. Presentation Date & Speakers: Mar-03-2015, Malcolm Weir, Chief Executive Officer.

Similar Private Companies By Industry

Company Name Region
SmithKline Beecham Limited Europe
J.M. Loveridge Ltd. Europe
Macfarlan Smith Ltd. Europe
CareFusion U.K. 244 Limited Europe
Trio Healthcare Limited Europe

Recent Private Companies Transactions

February 22, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Heptares Therapeutics Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at